Site-Specific Drug Delivery
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (31 March 2026) | Viewed by 1202
Special Issue Editor
Interests: colon-targeted drug delivery; prodrug; codrug; pathologically-targeted drug; molecular pharmacology of anti-colitic agents
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Site-specific drug delivery implies targeting a drug to a certain biological location. Targeted drug delivery leads to selective and effective distribution of a drug into the target site at therapeutic concentrations with limited access to non-target sites, thereby enhancing its therapeutic effectiveness and safety. Due to these therapeutic and toxicological advantages, the delivery technique, which is achieved by various targeting strategies utilizing small molecules, nucleic acid fragments (aptamers), synthetic peptides, recombinant monoclonal antibodies, and natural and genetically engineered cells, has been adopted in drug development and come into clinical reality. Pharmaceutical formulations including nanotechnology can not only be a different targeting strategy but also enhance the therapeutic performance of the aforementioned strategies. This Special Issue welcomes research articles relevant to site-specific drug delivery including biological barriers for it.
Prof. Dr. Yunjin Jung
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- site-specific drug delivery
- targeted drug delivery
- therapeutic effectiveness
- nanotechnology
- biological barrier
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
